|
CHK2 showed a very strong preference for arginine in position -3, excluding most other residues in that position. This feature is similar to consensus sequences determined for other members of the CaMK family, and it is also shared by DAPK3, which additionally showed a very strong selectivity for arginine in position -2. Importantly, for none of the four studied kinases the determined consensus sequences matched the activation segment phosphorylation sites (Figure 3C), but corresponded well with sequences of known substrates for the respective kinases.
Discussion This study reports the previously unknown structures for the three human protein kinases DAPK3, LOK and SLK. The structural data revealed that the activation segment, a key regulatory element of kinase function, may exchange with the activation segment of an adjacent kinase molecule forming an active kinase in trans conformation. Structural comparison, mutagenesis and biophysical characterization suggest a model for activation segment autophosphorylation, which may be common to kinases from diverse families.
Flexibility of the activation segment in the inactive state
The high degree of flexibility in a region that constitutes the substrate-binding site in inactive kinases raises the question of how activation segments are specifically recognized. The segment exchange observed in the four catalytic domain structures leads to ordering of the activation segment in the nonphosphorylated state. This conformation is stabilized by a large number of interactions at the dimer interface. Residues targeted for phosphorylation are generally in close proximity (between 9 and 12 Å) to the catalytic aspartate in nonphosphorylated segments, and only a small local reorganization would be sufficient to arrange these residues in positions competent for phosphoryl transfer. Dimerization has also been described for the dual-specificity kinases MEK1 and MEK2. However, no activation segment exchange has been reported for the published structures (Ohren et al, 2004).
The main function of activation segment phosphorylation in SLK and LOK is autoactivation. However, DAPK3 has been reported not to require activation segment phosphorylation for catalytic activity. This is supported by our observation that DAPK3 is autophosphorylated at two sites (S50 and T265) in the absence of a phosphorylation within the activation segment. Autophosphorylation at the activation segment residue T180 has been suggested to be of functional importance for DAPK3 activity, because a T180A mutant is resistant to activation and suppresses DAPK3 function in cells (Graves et al, 2005). Interestingly, the DAPK3 phosphorylation site at T180 is analogous to the second autophosphorylation site in CHK2 at T387, and the T387A mutant of CHK2 is unable to trigger the G1 checkpoint, suggesting that phosphorylation at this site is critical for CHK2 activity (Lee and Chung, 2001).
Active conformation of domain-exchanged kinases
The proposed mechanism for autophosphorylation requires that the activation segment-exchanged kinase dimers retain an active conformation. Comparison of active kinase structures shows that helix C is positioned such that a salt bridge between the active site lysine and the conserved C glutamate can form, provided this interaction is not perturbed by interaction with an inhibitor as was observed in the structure of the LOK/K00593 complex.
Comparison between the activation segment sequence of SLK and other STE kinases suggests that S189, and not T183, is the primary phosphorylation site. In the structure of diphosphorylated dimeric SLK, T183 forms a hydrogen bond network with the activation segment residues R187 and R186, whereas phosphorylation of S189 did not result in formation of new polar interactions in dimeric SLK. The length of the activation segment is invariant among the PAK and SLK/LOK families, suggesting that S189 may form similar interactions in monomeric SLK/LOK, as observed for the analogous residue in PAK4 (S474) (Eswaran et al, 2007). This suggests that the role of T183 phosphorylation is to promote activation segment phosphorylation at S189 positioned in close proximity to the catalytic aspartate (D155) of the interacting protomer (Figure 5C). This interpretation is supported strongly by the impairment of autophosphorylation observed for the T183A mutant. Multiple activation segment phosphorylation sites have been reported for a number of kinases. From our results, it could be deduced that these sites play functional roles in activation segment phosphorylation and kinase activation, but may be less relevant for the catalytic activity once the kinase is activated.
Activation segment phosphorylation on non-consensus sites
A common feature of the discussed kinases is that all activation segment autophosphorylation sites identified in this study or reported in the literature do not match the sequence requirements for consensus substrate binding or phosphorylation. Furthermore, it was shown recently that full-length, activated CHK2 does not recognize an isolated CHK2 kinase domain as a bona fide substrate despite rapid autophosphorylation (Oliver et al, 2006). Thus, the mechanism for the recognition of autophosphorylation residues differs from substrate recognition and likely requires dimerization of the catalytic domain as observed in the crystal structure.
In addition, improper activation across kinase cascades would also be prevented. For example, CHK1 shares a large number of substrates with CHK2. Yet, in the absence of dimerization and activation segment exchange, CHK1 cannot phosphorylate activation segment residues and activate CHK2, as they do not resemble CHK1 consensus substrates.
Requirement of additional domains that stabilize dimer formation
AUC demonstrated that dimerization is also observed in solution. However, the determined dissociation constants suggest that the studied catalytic domains require additional mechanisms to stabilize dimers and increase the effective concentrations of the kinase domains in vivo to achieve efficient dimerization. Accordingly, all kinases studied here possess additional dimerization domains adjacent to the kinase domain. In CHK2, dimerization is regulated by phosphorylation of the FHA domain residue T68 by the DNA damage sensor ATM (Ahn et al, 2002; Xu et al, 2006). Regulation of dimerization by post-translational modification offers an attractive model of how kinase activity may be controlled by dimerization. Several recent studies also strongly support the idea that DAPK3 dimerization is regulated by phosphorylation. Mutation of the leucine zipper present in the DAPK3 C terminus results in loss of self-association, autophosphorylation and a decrease in the ability of the enzyme to induce cell death upon overexpression (Kawai et al, 1998; Graves et al, 2005). Interestingly, the DAPK kinase domain itself is sufficient for self-association and this oligomerization might be relevant not only for autoactivation, but may also regulate crosstalk with other DAPK family members. Recently, it has been shown that DAPK3 and DAPK1, which share about 80% sequence identity, associate in cells and that the DAPK3 catalytic domain is sufficient for self- as well as hetero-association (Shani et al, 2004). The DAPK3 structure indicates that dimerization may be mediated by phosphorylation at S50, which is part of a hydrogen bond network at the dimer interface involving K167, R135 and E70 of the interacting kinase domain (Supplementary Figure S7B). Interestingly, S50 is located in the DAPK family-specific basic loop region that links the strand 3 with helix C, and interaction studies showed that mutation of conserved arginine residues in this region reduces dimerization of DAPK3 (Shani et al, 2004). To study the effect of S50 phosphorylation on dimerization, we coexpressed DAPK3 with -phosphatase and obtained a homogeneous, unphosphorylated protein sample. Indeed, AUC velocity experiments showed that the unphosphorylated DAPK3 kinase domain is entirely monomeric in solution (Supplementary Figure S7A). Furthermore, unphosphorylated DAPK3 crystallizes as a monomer (unpublished data). Based on these data, we propose a stepwise activation of DAPK3 comprising (a) autophosphorylation at consensus sites, (b) dimerization of the catalytic domain stabilized by phosphorylation at S50 and activation segment exchange, and (c) phosphorylation of the activation segment non-consensus site T180 (Supplementary Figure S7C).
As shown for SLK, activation segment phosphorylation weakens self-association. However, in the crystal structure, diphosphorylated SLK was still found dimeric. It is tempting to speculate that dimers of activated kinases may serve as a specificity filter that would allow only specific substrates with high affinity to the substrate-binding site to bind. Thus, they may lead to dissociation of the dimer and may be phosphorylated by the kinase. Such a model is supported by a recent report, on the dimeric state of the kinase domain of PAK2, where it was shown that the kinase dissociates into monomers upon addition of a high-affinity substrate (Pirruccello et al, 2006).
Implications for development of specific inhibitors
Targeting the inactive conformation of kinases has resulted in the development of a number of highly successful and specific kinases inhibitors. All kinases examined here represent potential targets for inhibitor development for cancer therapy: the DAPK family has been linked to misregulation of oncogenes (Gozuacik and Kimchi, 2006). A mutation in LOK (K277E) has been implicated in the development of testicular germ-cell tumours, and its role as an activator of polo-like kinases suggests that LOK-selective inhibitors may be beneficial for the treatment of certain tumour types (Bignell et al, 2006). The observed dimeric nature of the studied kinases may give rise to novel types of inhibitors. Activation segment exchange creates a pocket in the dimer interface adjacent to the ATP-binding site. This pocket is lined by the two strands 3 and 5, C as well as by residues of the interacting protomer activation segment (Supplementary Figure S8). Several high-affinity type I inhibitors have been cocrystallized with the kinases discussed here, constituting a suitable starting point for further design of such inhibitors.
Materials and methods Cloning, expression and purification
Catalytic domain residues were cloned into the vector pNIC28-Bsa4, by ligation-independent cloning (Stols et al, 2002). The vector includes a TEV-cleavable (*) N-terminal His6 tag (MHHHHHHSSGVDLGTENLYFQ*SM). Proteins were expressed in Escherichia coli and purified using immobilized Ni-affinity chromatography followed by proteolytic cleavage of the His6 tag and size-exclusion chromatography. Recombinant proteins were 95% pure as judged by SDS–PAGE and the correct molecular weight was confirmed using electrospray (ESI) MS. Unphosphorylated variants of SLK and LOK were obtained by treating the purified protein for 12 h with GST-lambda phosphatase. Phosphorylated SLK was obtained by incubating the recombinant protein with 5 mM ATP and 10 mM MgCl2 for 12 h. Autophosphorylation was carried out using 1.5 mM ATP, 3 mM MgCl2, 3 mM MnCl2 at 4°C for 48 h. Mutants were generated using the QuickChange kit (Stratagene) and were verified by DNA sequencing.
Crystallization
All crystals were obtained at 4°C using the sitting-drop vapour diffusion method.
SLK. Crystals of unphosphorylated and diphosphorylated SLK were obtained by mixing 100 nl of protein (10–12 mg/ml containing 1 mM Cdk1/2 Inhibitor III (K00546; Calbiochem)) with 50 nl of a well solution containing 16–18% PEG3350, 0.15 M KSCN, 10% ethylene glycol, 0.1 M bis-Tris propane, pH 6.5. Crystals of the K00606 complex were obtained under the same conditions using predominantly monophosphorylated protein (10 mg/ml) containing 1 mM of the inhibitor. Crystals of apo-SLK were obtained by mixing protein (10.5 mg/ml) with reservoir solution (20% PEG3350, 0.2 M KSCN, 10% ethylene glycol, 0.1 M bis-Tris propane, pH 7.5 at a ratio of 2:1). Prior to vitrification in liquid nitrogen, all crystals were briefly soaked in mother liquor supplemented with 15% ethylene glycol.
LOK. Crystals were obtained by mixing 100 nl of protein solution (12.8 mg/ml containing 1 mM K00593/SU11274 (3-(1-(3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-2H-pyrrol-2-yl)-meth-(Z)-ylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulphonic acid (3-chloro-phenyl)-methyl-amide)) with 50 nl of a well solution containing 45% PEG300, 0.24 M calcium acetate, 0.1 M sodium cacodylate, pH 6.5). Crystals were vitirified directly in liquid nitrogen prior to data collection.
DAPK3. Crystals were grown from a drop consisting of 150 nl protein (10.3 mg/ml) containing 1 mM K00225/Pyridone 6 (2-(1,1-dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz(4,5-f)isoquinolin-7-one) and 50 nl well solution. The drop was equilibrated against well solution containing 30% PEG1000, 0.1 M succinic acid-phosphate-glycine (SPG) buffer pH 8.0. Prior to flash freezing, the crystals were briefly soaked in mother liquor supplemented with 20% ethylene glycol.
Data collection and processing
Diffraction data were collected from flash-frozen crystals at 100 K on beamline X10SA at the Swiss Light Source (SLS). Images were recorded on a MAR CCD detector (Mar Research), indexed and integrated using MOSFLM and scaled using SCALA in the CCP4 suite of programs. Data collection statistics and cell parameters are listed in Table I.
Structure solution and refinement
SLK, LOK. The structure of the SLK/K00546 co-complex was solved by molecular replacement using PHASER (Storoni et al, 2004) with the coordinates of human TAO2 kinase (PDB code: 1U5R) that had been sequence-truncated using CHAINSAW (Schwarzenbacher et al, 2004) as a search model. The refined SLK/K00546 complex was then used as a starting model, after rigid-body refinement in REFMAC5 (Murshudov et al, 1997), for all other SLK complexes. The LOK structure was subsequently solved using the SLK/K00546 structure.
DAPK3. The structure was solved by molecular replacement using PHASER with a composite model comprising coordinates from DAPK3 (PDB code: 1YRP) and DAPK1 (PDB code 1JKT/1WVX) as a search model. Initial automated model building was carried out using ARP/WARP (Morris et al, 2003). In all cases, iterative rounds of restrained refinement using REFMAC5 (Murshudov et al, 1997) with appropriate TLS restraints, interspersed with manual rebuilding using Coot (Emsley and Cowtan, 2004). Final models were validated using MOLPROBITY (Davis et al, 2004, 2007).
Identification of inhibitors
Thermal denaturation experiments were carried out using a real-time PCR (Mx3005p, Stratagene) as described previously (Vedadi et al, 2006; Niesen et al, 2007). K00546 and K00589 were purchased from Calbiochem. K00606 was a generous gift from Professor Kevan Shokat (University of California).
Analytical ultracentrifugation
Sedimentation velocity experiments were carried out on a Beckman XL-I Analytical Ultracentrifuge equipped with a Ti-50 rotor. Protein samples were studied at a concentration of 15, 30 and 60 M in 10 mM HEPES, pH 7.4, 150 mM NaCl, employing a rotor speed of 50 000 rpm. Radial absorbance scans were collected in 1 min intervals. Data were analysed using SEDFIT (Brown and Schuck, 2006) to calculate c(s) distributions. The software package SEDNTERP (http://www.jphilo.mailway.com) was used to normalize the obtained sedimentation coefficient values to the corresponding values in water at 20°C,
. Sedimentation equilibrium experiments were performed at 4°C and a protein concentration of 15, 30 and 60 M. The dissociation constant, Kd, was calculated from the fitted apparent association constant, Ka,obs, according to the equation
where d is the optical pathlength and 290 the extinction coefficient at 290 nm.
Determination of peptide phosphorylation specificity
Phosphorylation motifs for SLK, CHK2 and DAPK3 were determined using a positional scanning peptide library approach essentially as described previously (Hutti et al, 2004). Reactions were carried out in multiwell plates in 50 mM HEPES, pH 7.4, 10 mM MnCl2, 1 mM DTT, 0.1% Tween 20, 100 M ATP (including 0.3 Ci/ l -[33P]-ATP), 50 M peptide substrate and 50 g/ml kinase for 2–4 h at 30°C. Peptide substrates had the general sequence YAXXXXX-S/T-XXXXAGKK(biotin), where S/T represents an even mixture of serine and threonine, K(biotin) is -(biotinamidocaproyl)lysine and X is a equimolar mixture of the 17 amino acids excluding cysteine, serine and threonine. Each well contained a distinct peptide in which one of the X positions was replaced with one of the 20 residues (one of the unmodified proteogenic amino acids excluding S and T). In addition, three additional wells were included that contained either no peptide, the peptide YAXXXXX-S-XXXXAGKK(biotin) or the peptide YAXXXXX-T-XXXXAGKK(biotin), to test phosphoacceptor residue preference. At the end of the incubation time, aliquots of each reaction were spotted onto streptavidin membrane, which was processed as described previously (Hutti et al, 2004).
Structure analysis
To facilitate analysis, all coordinates were superimposed onto a common frame using the SLKA/K00546 complex as a reference using THESEUS-3D (Theobald and Wuttke, 2006). The dimer interface was characterized using the MSD-PISA server (http://www.ebi.ac.uk/msd-srv/prot_i nt/pistart.html). Figures 1B, 2, 3A and B, 5A–C and 6 were created using PYMOL (DeLano, 2002). Atomic coordinates and structure factors have been deposited in the PDB, accession codes 2J51, 2UV2, 2JFL, 2JFM, 2J7T and 2J90.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
Acknowledgements
We thank Dr Oleg Fedorov for inhibitor screening support. The Structural Genomics Consortium is a registered charity (number 1097737) that receives funds from the Canadian Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co Inc., the Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research and the Wellcome Trust. LHP and AWO gratefully acknowledge the support of a Programme Grant from Cancer Research UK. BET and SAP are supported by the National Institutes of Health (GM079498).
References
Ahn JY, Li X, Davis HL, Canman CE (2002) Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 277: 19389–19395 | Article | PubMed | ISI | ChemPort | Bignell G, Smith R, Hunter C, Stephens P, Davies H, Greenman C, Teague J, Butler A, Edkins S, Stevens C, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K et al (2006) Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45: 42–46 | Article | PubMed | ChemPort | Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA (1999) Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem 274: 8746–8756 | Article | PubMed | ISI | ChemPort | Brown PH, Schuck P (2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 90: 4651–4661 | Article | PubMed | ChemPort | Burakov AV, Kovalenko OV, Potekhina ES, Nadezhdina ES, Zinovkina LA (2005) LOSK (SLK) protein kinase activity is necessary for microtubule organization in the interphase cell centrosome. Dokl Biol Sci 403: 317–319 | Article | PubMed | ChemPort | Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH (2003) Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 22: 494–501 | Article | PubMed | ChemPort | Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Bryan Arendall III W, Snoeyink J, Richardson JS, Richardson DC (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 89: 90 Davis IW, Murray LW, Richardson JS, Richardson DC (2004) MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32: W615–W619 | Article | PubMed | ISI | ChemPort | DeLano WL (2002) The PyMOL Molecular Graphics System. Paolo Alto, CA, USA: DeLano Scientific Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D 60: 2126–2132 | Article | PubMed | ISI | ChemPort | Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O, Deacon SW, Peterson JR, Knapp S (2007) Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15: 201–213 | Article | PubMed | ChemPort | Goldberg J, Nairn AC, Kuriyan J (1996) Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I. Cell 84: 875–887 | Article | PubMed | ISI | ChemPort | Gozuacik D, Kimchi A (2006) DAPk protein family and cancer. Autophagy 2: 74–79 | PubMed | ChemPort | Graves PR, Winkfield KM, Haystead TA (2005) Regulation of zipper-interacting protein kinase activity in vitro and in vivo by multisite phosphorylation. J Biol Chem 280: 9363–9374 | Article | PubMed | ChemPort | Hu J, Liu J, Ghirlando R, Saltiel AR, Hubbard SR (2003) Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol Cell 12: 1379–1389 | Article | PubMed | ISI | ChemPort | Hutti JE, Jarrell ET, Chang JD, Abbott DW, Storz P, Toker A, Cantley LC, Turk BE (2004) A rapid method for determining protein kinase phosphorylation specificity. Nat Methods 1: 27–29 | Article | PubMed | ChemPort | Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S (1998) ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol Cell Biol 18: 1642–1651 | PubMed | ISI | ChemPort | Lee CH, Chung JH (2001) The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem 276: 30537–30541 | Article | PubMed | ISI | ChemPort | Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V (2006) A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24: 627–633 | Article | PubMed | ISI | ChemPort | Lochhead PA, Sibbet G, Morrice N, Cleghon V (2005) Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 121: 925–936 | Article | PubMed | ISI | ChemPort | Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC (2001) Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 19: 397–421 | Article | PubMed | ISI | ChemPort | Meng W, Swenson LL, Fitzgibbon MJ, Hayakawa K, Ter Haar E, Behrens AE, Fulghum JR, Lippke JA (2002) Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 277: 37401–37405 | Article | PubMed | ISI | ChemPort | Morris RJ, Perrakis A, Lamzin VS (2003) ARP/wARP and automatic interpretation of protein electron density maps. Methods Enzymol 374: 229–244 | Article | PubMed | ISI | ChemPort | Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 53: 240–255 | Article | PubMed | ISI | ChemPort | Niesen FH, Berglund H, Vedadi M (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2: 2212–2221 | Article | PubMed | ChemPort | Nolen B, Taylor S, Ghosh G (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15: 661–675 | Article | PubMed | ISI | ChemPort | O'Reilly PG, Wagner S, Franks DJ, Cailliau K, Browaeys E, Dissous C, Sabourin LA (2005) The Ste20-like kinase SLK is required for cell cycle progression through G2. J Biol Chem 280: 42383–42390 | Article | PubMed | Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S et al (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192–1197 | Article | PubMed | ISI | ChemPort | Oliver AW, Knapp S, Pearl LH (2007) Activation segment exchange: a common mechanism of kinase autophosphorylation? Trends Biochem Sci 32: 351–356 | Article | PubMed | ChemPort | Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mittnacht S, Pearl LH (2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 25: 3179–3190 | Article | PubMed | ChemPort | Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J (2006) Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 66: 9714–9721 | Article | PubMed | ChemPort | Pirruccello M, Sondermann H, Pelton JG, Pellicena P, Hoelz A, Chernoff J, Wemmer DE, Kuriyan J (2006) A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases. J Mol Biol 361: 312–326 | Article | PubMed | ChemPort | Ponstingl H, Henrick K, Thornton JM (2000) Discriminating between homodimeric and monomeric proteins in the crystalline state. Proteins 41: 47–57 | Article | PubMed | ChemPort | Prowse CN, Lew J (2001) Mechanism of activation of ERK2 by dual phosphorylation. J Biol Chem 276: 99–103 | Article | PubMed | ISI | ChemPort | Rellos P, Ivins FJ, Baxter JE, Pike A, Nott TJ, Parkinson DM, Das S, Howell S, Fedorov O, Shen QY, Fry AM, Knapp S, Smerdon SJ (2007) Structure and regulation of the human Nek2 centrosomal kinase. J Biol Chem 282: 6833–6842 | Article | PubMed | ChemPort | Rosenberg OS, Deindl S, Comolli LR, Hoelz A, Downing KH, Nairn AC, Kuriyan J (2006) Oligomerization states of the association domain and the holoenyzme of Ca2+/CaM kinase II. FEBS J 273: 682–694 | Article | |